Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepenofovir Fumarate Tablets multiple-dose study in chronic hepatitis B
CTR20223254Phase 2Active
- Sponsor
- Xi'an Xintong Pharmaceutical
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Hepenofovir in Chronic Hepatitis B (CHB) (4 arms), sponsored by Xi'an Xintong Pharmaceutical. Started Dec 2022; status: active.
02
Drugs
Hepenofovir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20223254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223254.